Metabolic syndrome and cancer risk
Introduction
Metabolic syndrome is defined as a combination of cardiovascular risk factors which include increased body mass index (or waist circumference), blood pressure, glycemia, and serum triglycerides, as well as a decrease in high-density lipoprotein cholesterol.1, 2, 3, 4
Interestingly, most components of metabolic syndrome have each been linked in some way to the development of cancer. Hypertension may increase cancer risk by blocking and subsequently modifying apoptosis, thereby affecting cell turnover.5, 6 Several studies showed a positive relationship between diabetes and pancreatic and liver cancers caused by the insulin excess which promotes the development of cancer cells in the liver and pancreas.7, 8, 9, 10, 11 Obesity is a major risk factor for cancer; prospective studies indicate that overweight and obesity account for 14% of all cancer deaths in men and 20% in women.12 Obesity is implicated in aetiology and progression of cancer at multiple cancer sites by means of signalling pathways that regulate key functions, including cancer cell proliferation, apoptosis, metastasis, and angiogenesis.13, 14, 15
Yet, bearing such evidence, based on the related components of metabolic syndrome, epidemiological studies linking metabolic syndrome to cancer are scarce.16, 17, 18, 19, 20
The purpose of this study is to explore the relationship between metabolic syndrome and cancer risk. Referring to the health information system and to the Cancer Registry of Milan, subjects simultaneously treated with hypoglycaemic, anti-hypertensive and hypolipemics drugs were assigned to a pharmacological diagnosis of metabolic syndrome. Specifically, under the hypothesis that those subjects have a higher risk of developing cancer, we systematically analysed their risk cancer differences with the general population across all cancer sites.
Section snippets
Materials and methods
This study was carried out using Milan’s Health Authority information system, which covers the largest metropolitan population in the North of Italy (about 1,300,000 inhabitants).
All drugs prescribed to the resident population of Milan are listed in the Pharmaceutical Prescriptions Archive and coded with the Anatomical Therapeutic Chemical (ATC) classification. All pharmaceutical prescriptions in the time period between 1 January 1999 and 31 December 2005 (N = 42,626,531) were retrieved to
Results
A total of 16,677 subjects exposed simultaneously to antihypertensive, hypoglycaemic and hypolypemic treatments were identified and enrolled in the study.
Case follow-up lasted up to 8-years, with an average follow up period of 2.7 years, and a total of 45,828 person-years. During the study period 823 incidents cancers were identified. Table 1 shows the absolute and the expected frequencies of new occurrences by site as classified by ICD-X.
The expected number of invasive cancers, derived from
Discussion
Adopting a pharmacologically based definition of metabolic syndrome, our study identified a positive association of this nosological entity with several cancer sites. In particular, the strongest associations were found with pancreatic cancer in men and colorectal cancer in women, but remarkable risk increases were identified for several sites (liver cancer in males and biliary tract and corpus uteri in females).
Our study has several important strengths: it is population based; results are
Conflict of interest statement
None declared.
References (27)
- et al.
The metabolic syndrome
Lancet
(2005) - et al.
The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans
Am J Gastroenterol
(2001) - et al.
Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
Circulation
(2004) Metabolic syndrome
Circulation
(2007)Cancer and hypertension. An unresolved issue
Hypertension
(1996)- et al.
Hypertension and hormone-related neoplasms in women
Hypertension
(1999) Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?
J Am Coll Cardiol
(1999)- et al.
Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark
J Natl Cancer Inst
(1977) - et al.
Cancer incidence in patients with type 1 diabetes mellitus: A population-based cohort study in Sweden
J Natl Cancer Inst
(2003) - et al.
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study
Gut
(2005)
Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay area, California
Cancer Epidemiol Biomarkers Prev
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults
N Engl J Med
Body weight, physical activity and cancer
IARC Sci Publ
Cited by (182)
The impact of metabolic syndrome in breast reconstruction decision-making and postoperative outcomes: A nationwide analysis
2024, Journal of Plastic, Reconstructive and Aesthetic SurgeryMetabolic syndrome is linked to the incidence of pancreatic cancer
2024, eClinicalMedicineNonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality
2023, Clinical Gastroenterology and HepatologyPersistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study
2021, European Journal of CancerCitation Excerpt :Only a few previous studies have investigated the association between baseline MetS and CCA risk without considering MetS persistence. These few cohort studies on the association between MetS and CCA have reported inconsistent results, with a null [11] or a positive association only in females [12]. Previous case–control studies have also shown inconsistent results, with a positive [13–17] or null association [18].